Search

Displaying results 9131 - 9140 of 9613 in total
  1. Drug

    Resatorvid

    go.drugbank.com/drugs/DB05943
    Investigational

    Resatorvid is an investigational compound designed for the treatment of severe sepsis.

  2. Drug

    XAV-19

    go.drugbank.com/drugs/DB15895
    Investigational

    As of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety and efficacy of XAV-19 (NCT04453384). … Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University Hospital to test the treatment in patients[L16553,L16558].

  3. Drug

    NCX 1015

    go.drugbank.com/drugs/DB05825
    Experimental

    NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.

  4. Drug

    Triphosphoric acid

    go.drugbank.com/drugs/DB03896
    Experimental

    Used as water softener, peptizing agent, emulsifier & dispersing agent; ingredient of cleansers; meat preservative.

  5. Drug

    VPM4001

    go.drugbank.com/drugs/DB05089
    Experimental

    Interferon-γ enhances presentation of tumour antigens, whereas interleukin-2 stimulates T cells. … It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ).

  6. Drug

    Bisegliptin

    go.drugbank.com/drugs/DB06127
    Investigational

    It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion

  7. Drug

    N-(3-carboxypropanoyl)-L-norvaline

    go.drugbank.com/drugs/DB08554
    Experimental

    These are compounds containing an alpha amino acid which bears an acyl group at his terminal nitrogen atom.

  8. Drug

    EpiVacCorona

    go.drugbank.com/drugs/DB16439
    Investigational

    It is currently being tested in Phase I/II clinical trials for safety and immunogenicity (NCT04527575)[L30608, L30613].

  9. Drug

    OSU-6162

    go.drugbank.com/drugs/DB19178
    Investigational

    OSU-6162 is under investigation in clinical trial NCT05641623 (OSU6162 as Add-on in Ssri/snri-resistant Depression).

  10. Drug

    3-amino-5-phenylpentane

    go.drugbank.com/drugs/DB02869
    Experimental

    These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by a propan-1-amine. 3-amino-5-phenylpentane targets the proteins cathepsin K